Camrelizumab for Injection ;

This product is indicated for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have undergone at least second-line systemic chemotherapy.
This indication was granted conditional approval based on objective response rate and duration of response results from a single-arm clinical trial. Suitable
Full approval will depend on confirmation of the efficacy of camrelizumab in planned confirmatory randomized controlled clinical trials.
Significant clinical benefit over standard treatment.
2. This product is used for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib treatment and/or oxaliplatin-containing systemic chemotherapy.
This indication was granted conditional approval based on objective response rate and overall survival results from a Phase II clinical trial. This indication
Full approval will depend on planned confirmatory randomized controlled clinical trials confirming the efficacy of camrelizumab compared with
Significant clinical benefit from standard treatment.
3. This product combined with pemetrexed and carboplatin is suitable for epidermal growth factor receptor (EGFR) gene mutation-negative and anaplastic lymphoma.
First-line treatment of ALK-negative, unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
treatment.
4. This product is used for patients with locally advanced or metastatic esophageal squamous cell carcinoma whose disease has progressed or is intolerable after receiving first-line chemotherapy.
treat.
5. This product is used for the treatment of patients with advanced nasopharyngeal carcinoma whose disease has progressed or is intolerable after receiving second-line or above chemotherapy.
6. This product is used in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma.